



Cornerstone Pharmaceuticals, Inc  
1 Duncan Drive  
Cranbury, NJ 08512

Media Contact: Meghan Weber  
Liza Sullivan & Associates  
(917) 399-8713

## **CORNERSTONE PHARMACEUTICALS ADDS NEW CLINICAL TRIAL SITE FOR THE EVALUATION OF ITS FIRST IN CLASS ANTI-CANCER AGENT CPI-613**

**CRANBURY, NJ, February 8, 2010** – Cornerstone Pharmaceuticals, Inc. (<http://www.cornerstonepharma.com>), the private pharmaceutical company behind experimental cancer drug CPI-613 - with multiple ongoing phase I/II clinical trials - has announced it has added Pivotal Research Centers ([www.pivotalresearch.com](http://www.pivotalresearch.com)), operators of several medical research facilities in the western U.S., to its roster of clinical trial sites for its single agent phase I/II clinical trial at Pivotal's Peoria, Arizona location.

"This is a very significant development for our Company as we expand the clinical trials of CPI-613 and continue to partner with institutions that share our vision of helping people to better manage their affliction," commented Dr. Robert Shorr, CEO for Cornerstone Pharmaceuticals. "I welcome Pivotal Research Centers to the Cornerstone network."

Divis Khaira, MD, Clinical Trial Investigator for Pivotal Research Center said, "We are very pleased to join together with Cornerstone as a test site location and share their core mission to endeavor to bring CPI-613 through its development and ultimately to those in need to make various cancers more manageable and perhaps even treatable."

CPI-613 is the initial candidate to emerge from Cornerstone's Altered Energy Metabolism Directed (AEMD) technology platform. CPI-613 is the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes that may be common to many cancer types. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer, a cancer type that typically has a poor prognosis, spreads rapidly and often goes undetected in its early stages.

### **About Pivotal Research Centers**

Pivotal Research Centers specializes in high quality clinical research. It is staffed by medical professionals who understand and care about the people who volunteer for the clinical studies. Our personnel are experts in their fields and have a commitment to conducting the clinical trials in a relaxed and pleasant setting. Pivotal Research Centers was established in 1993 and has grown into three locations; two sites in the Phoenix Metropolitan area (Peoria /Sun City and Mesa), and a site in the Metropolitan area of Salt Lake City. For further information call 1-866-STUDY 21 / 1-866-788-3921 or visit [www.pivotalresearch.com](http://www.pivotalresearch.com).

### **About Cornerstone Pharmaceuticals**

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing



on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. Cornerstone is the only company that currently has a drug in clinical trials targeting certain key enzymes crucial to cancer cell metabolism. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated. Its lead drug, CPI-613, is currently being evaluated in three ongoing Phase I and Phase I/II clinical trials in a variety of tumor types.

### **About CPI-613**

CPI-613 is the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes considered to be common to many, if not all, cancer types and not present in normal cells. Patients with solid tumors and hematologic cancers are currently being enrolled in multiple Phase I and Phase I/II human clinical trials evaluating CPI-613. These trials include a Phase I/II single agent trial for patients with solid tumors who have failed all other therapy options, a Phase I/II combination trial with gemcitabine in newly diagnosed or relapsed patients, and a single agent trial in hematologic malignancies. CPI-613 was granted orphan drug status by the US FDA for pancreatic cancer, which has a poor prognosis, spreads rapidly and often goes undetected in its early stages. For further information, visit <http://www.cornerstonepharma.com>. Or contact: Meghan Weber at (917) 399-8713.

# # #

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.